We are delighted to announce that Biovault Family has been awarded the Cellular Therapy Services (CSM) Qualification which is based on our current accreditation status with the Association for the Advancement of Blood and Biotherapies (AABB).
This new qualification was announced in January 2022 and recognises Biovault Family’s expertise, capability and practices related to cellular therapy services such as umbilical cord blood and tissue banking.
It means that our company meets or exceeds AABB’s evidence-based Cellular Therapy Standards for the collection, storage and/or processing of cellular starting materials, including umbilical cord blood and tissue.
This is excellent news for Biovault Family and further verification that we remain committed to quality and excellence in offering personalised cord blood and tissue processing and storage services to parents who wish to bank their babies’ umbilical cord stem cells.
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.